GT Biopharma, Inc.

GTBP

US36254L3087

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 18/05/2024 am IST			5-day change	1st Jan Change
3.12 ^USD	-4.59%		-3.36%	-59.22%

26/03	GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
01/02	GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	MT

GT Biopharma, Inc. Announces Gregory Berk, President of Research & Development and Chief Medical Officer, Is no Longer Employee

December 14, 2022 at 03:00 am IST

GT Biopharma, Inc. announced that effective December 8, 2022, Dr. Gregory Berk, President of Research & Development and Chief Medical Officer, is no longer employed by the Registrant.

Latest news about GT Biopharma, Inc.

GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	01/02	MT
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	04/12	CI
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting	06/11	CI
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01/11	CI
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/23/07	CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Index	23/23/23	CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Growth Index	23/23/23	CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell 3000E Growth Index	23/23/23	CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell 3000E Index	23/23/23	CI
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
North American Morning Briefing : Hopes Build for -3-	15/23/15	DJ
GT Biopharma, Inc. Announces Board Changes	04/23/04	CI
Certain Warrants of GT Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 5-APR-2023.	05/23/05	CI
Certain Common Stock of GT Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 5-APR-2023.	05/23/05	CI
North American Morning Briefing : Traders Await -3-	31/23/31	DJ
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31	CI
North American Morning Briefing : Stock Futures -2-	24/23/24	DJ
Beyond Air Affiliate Beyond Cancer Names Gavin Choy Chief Operating Officer	30/23/30	MT
EF Hutton Starts GT Biopharma at Hold With $2 Price Target	05/23/05	MT
GT Biopharma to Sell 6.5 Million Shares and Warrants, Expects Gross Proceeds of $6.5 Million	30/22/30	MT
Gt Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer	14/22/14	CI
GT Biopharma, Inc. Announces Gregory Berk, President of Research & Development and Chief Medical Officer, Is no Longer Employee	14/22/14	CI
GT Biopharma, Fate Therapeutics Say Preclinical Data Shows Potential of New Approach to Treat Leukemia	13/22/13	MT
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	01/22/01	CI

GT Biopharma, Inc. specializes in the research and development of therapeutic products used primarily for the treatment of cancer and disorders of the central nervous system. The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).

Sector

Pharmaceuticals

Calendar

25/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.27 USD

Average target price

150 USD

Spread / Average Target

+4,487.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GT BIOPHARMA, INC.	-59.22%	4.51M
ELI LILLY AND COMPANY	+32.09%	694B
NOVO NORDISK A/S	+29.39%	593B
JOHNSON & JOHNSON	-1.34%	371B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+7.39%	290B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	209B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+8.49%	169B

Other Pharmaceuticals

GT Biopharma, Inc.

Equities

GTBP

US36254L3087

Pharmaceuticals

GT Biopharma, Inc. Announces Gregory Berk, President of Research & Development and Chief Medical Officer, Is no Longer Employee

Latest news about GT Biopharma, Inc.

Chart GT Biopharma, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals